title: [The significance of immunohistochemistry in the investigation of liver neoplasms: differential diagnosis, prognostic markers].
abstract: The immunohistochemical investigation used 55 primary hepatic tumors (hepatocellular carcinoma (HCC)--32, cholangiocellular carcinoma (CCC)--23). Wide panels of such antibodies as hepatocytic marker (Hep Par--1) CK-8, CK-19, polyclonal CEA, CD10, alpha-fetoprotein, TTF-1 as well as proliferative features of HCC (Ki-67) including regulators of stage-to-stage transition through mitoses of tumor cells (cyclin-D1 and A, genes p53 and RB), unrestricted tumor cell mitosis (telomerases), and intercellular adhesion marker (beta-catenin) were employed for differential diagnosis of neoplasia. The most efficient marker HCC was Hep Par--l (sensitivity--100%, specificity--92%) while the sensitivity of CCC (CK-19) was 83% and specificity--78%. Of particular importance for differentiation between HCC and CCC were the nature of microcirculatory flow identifiable with the aid of CD31 and presence of pseudocapsule in HCC detected by means of calponin. CEA and CD10 played a part too while the remaining markers were either expressed very seldom (alpha-fetoprotein) or absent (TTF-1). Most nuclear antigens (Ki-67, cyclin-A, p53 and RB) were intensely expressed in poorly-differentiated HCC cells. Cyclin-D1 and mutated suppressor-gene p53 expression involved lowered overall and relapse-free survival.
authors.forename: K M
authors.initials: KM
authors.lastname: Pozharisskiĭ
authors.forename: D A
authors.initials: DA
authors.lastname: Granov
authors.forename: V P
authors.initials: VP
authors.lastname: Ten
authors.forename: A G
authors.initials: AG
authors.lastname: Kubaĭbergenova
authors.forename: E E
authors.initials: EE
authors.lastname: Leenman
authors.forename: A I
authors.initials: AI
authors.lastname: Rasskazov
mesh_terms: D000328:Adult; D000368:Aged; D001650:Bile Duct Neoplasms / Q000175:diagnosis; D001653:Bile Ducts, Intrahepatic; D014408:Biomarkers, Tumor / Q000032:analysis*; D002135:Calcium-Binding Proteins / Q000032:analysis; D002272:Carcinoembryonic Antigen / Q000032:analysis; D006528:Carcinoma, Hepatocellular / Q000737:chemistry* / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D018281:Cholangiocarcinoma / Q000175:diagnosis; D019925:Cyclin A / Q000032:analysis; D056741:Cyclin D; D016213:Cyclins / Q000032:analysis; D004268:DNA-Binding Proteins / Q000032:analysis; D003937:Diagnosis, Differential; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016161:Genes, Retinoblastoma; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D053539:Keratin-19; D053533:Keratin-8; D019394:Ki-67 Antigen / Q000032:analysis; D008113:Liver Neoplasms / Q000737:chemistry* / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000556:secondary; D008297:Male; D008840:Microfilament Proteins / Q000032:analysis; D008875:Middle Aged; D015260:Neprilysin / Q000032:analysis; D011379:Prognosis; D012307:Risk Factors; D016019:Survival Analysis; D014157:Transcription Factors; D000509:alpha-Fetoproteins / Q000032:analysis; D051176:beta Catenin / Q000032:analysis; D000096985:Calponins
chemical_list: D014408:Biomarkers, Tumor; D002135:Calcium-Binding Proteins; D002272:Carcinoembryonic Antigen; D019925:Cyclin A; D056741:Cyclin D; D016213:Cyclins; D004268:DNA-Binding Proteins; D053539:Keratin-19; D053533:Keratin-8; D019394:Ki-67 Antigen; D008840:Microfilament Proteins; D015260:Neprilysin; D014157:Transcription Factors; D000509:alpha-Fetoproteins; D051176:beta Catenin; D000096985:Calponins; C097353:AFP protein, human; C495270:CTNNB1 protein, human; C504003:TTF1 protein, human